In a bold move that is addressing consumer concerns to treat skin diseases and skin care using alternative treatments using more natural ingredients, 3Sixty BioMedicine has recently launched the cutting-edge ‘Cape Sativa’ brand into the South African market. 

Cape Sativa Everyday cream is a cannabidiol (CBD) infused lotion that is formulated to moisturize and repair skin, increase elasticity and provide an anti-aging factor. CBD has proven anti-inflammatory and antioxidant properties, which makes it suitable for everyday use and in dry skin conditions. It is ‘paraben-free’ and thus suitable for sensitive skin. 

With the vision of ‘Improving livelihood, improving lives’, the launch of this ‘first-ever’ product to the SA market meets real consumer needs and addresses a gap in the market. The launch of this product at this time positions 3Sixty BioMedicine as leaders when it comes to CBD orientated treatments.

Under the ‘Cape Sativa’ brand there will be the development of other CBD based products for the management of dermatological conditions. Recently, literature has begun to describe the promising role of cannabinoids in the treatment of dermatologic conditions, among them, inflammatory skin diseases such as: acne, pruritus; psoriasis; allergic contact and atopic dermatitis.

BUSTING MYTHS & MISCONCEPTIONS

Cannabidiol is the second most prevalent of the active ingredients of cannabis (marijuana). While CBD is an essential component of medical marijuana, it is derived directly from the hemp plant, which is a cousin of the marijuana plant. While CBD is a component of marijuana (one of hundreds), by itself it does not cause a “high”. 

According to a report from the World Health Organization, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health related problems associated with the use of pure CBD.” In September 2018 a groundbreaking ruling by South Africa’s Constitutional Court ruled in favour of cannabis use by South Africans and included an exemption regarding CBD-containing products released by the SA Health Products Regulatory Authority (SAHPRA). 

Further to these important changes in the SA legislative framework pertaining to cannabis and in particular CBD, 3Sixty BioMedicine’s CEO, Walter Mbatha, believes that with the growing number of studies and research now available about the health benefits of one of the most abundant cannabinoids found in hemp; CBD is not only being considered as the future of beauty and wellness products worldwide – but in South Africa particularly. 

In October 2019, South Africa’s top health and beauty retailers, Clicks and Dis-Chem, listed CBD infused products in their stores and already there are a number of reputable pharmaceutical companies lined up to create and launch premium CBD products and ranges that are cultivated naturally, contain zero THC, are 100% organic, and most importantly – are certified and safe. 

“The reason for the interest and intensified focus on CBD is that when used in skin-care products, the ingredient’s anti-inflammatory properties can help calm and soothe irritation, reduce breakouts and moisturize without clogging pores. It’s these findings that prompted 3Sixty BioMedicine to invest in and develop a CBD based product range under the ‘Cape Sativa’ banner for the management of dermatological conditions,” said Mbatha.

Mbatha added that the company’s bold move to be one of the pioneer companies producing quality CBD based products in the health and beauty space, despite CBD-infused products are still considered the ‘new’ kid on the block, aligns with 3Sixty’s business vision to create and offer local consumers products and treatments that treat common health conditions using more natural ingredients. 

“These are exciting times for the SA market but as the market and number of CBD products grows, so will the need for the general SA public and healthcare practitioners to educate themselves about the difference between reputable CBD companies and their offerings versus opportunistic businesses producing cheaper, inferior products”, Mbatha concluded.